{
    "organizations": [],
    "uuid": "7c79c418640fd850eb6889c9312539f041538a87",
    "author": "Reuters Editorial",
    "url": "https://www.reuters.com/article/brief-corcept-therapeutics-q4-gaap-earni/brief-corcept-therapeutics-q4-gaap-earnings-per-share-0-77-idUSASB0C73Y",
    "ord_in_thread": 0,
    "title": "BRIEF-Corcept Therapeutics Q4 GAAP Earnings Per Share $0.77",
    "locations": [],
    "highlightText": "",
    "language": "english",
    "persons": [],
    "text": "Feb 22 (Reuters) - Corcept Therapeutics Inc:\n* CORCEPT THERAPEUTICS ANNOUNCES 2017 FINANCIAL RESULTS AND POSITIVE INTERIM RESULTS OF RELACORILANT PHASE 2 TRIAL\n* Q4 GAAP EARNINGS PER SHARE $0.77 * Q4 REVENUE ROSE 124 PERCENT TO $53.3 MILLION * SEES FY 2018 REVENUE $275 MILLION TO $300 MILLION * SEES FY 2017 REVENUE $159.2 MILLION * QUARTERLY NON-GAAP NET INCOME PER SHARE $0.19\n* Q4 EARNINGS PER SHARE VIEW $0.18, REVENUE VIEW $53.7 MILLION -- THOMSON REUTERS I/B/E/S\n* CORCEPT THERAPEUTICS - ‍ INTERIM RESULTS OF RELACORILANT PHASE 2 TRIAL SHOW NO EVIDENCE OF PROGESTERONE RECEPTOR AFFINITY; NO SERIOUS ADVERSE EVENTS​\n* ‍ RELACORILANT TRIAL SHOWS STATISTICALLY SIGNIFICANT, DOSE-DEPENDENT IMPROVEMENTS IN GLUCOSE TOLERANCE , SERUM OSTEOCALCIN​ Source text for Eikon: Further company coverage:\n ",
    "published": "2018-02-23T05:42:00.000+02:00",
    "crawled": "2018-02-23T16:14:44.011+02:00",
    "highlightTitle": "",
    "preprocessed_text": [
        "feb",
        "reuters",
        "corcept",
        "therapeutic",
        "inc",
        "corcept",
        "therapeutic",
        "announces",
        "financial",
        "result",
        "positive",
        "interim",
        "result",
        "relacorilant",
        "phase",
        "trial",
        "q4",
        "gaap",
        "earnings",
        "per",
        "share",
        "q4",
        "revenue",
        "rose",
        "percent",
        "million",
        "see",
        "fy",
        "revenue",
        "million",
        "million",
        "see",
        "fy",
        "revenue",
        "million",
        "quarterly",
        "net",
        "income",
        "per",
        "share",
        "q4",
        "earnings",
        "per",
        "share",
        "view",
        "revenue",
        "view",
        "million",
        "thomson",
        "reuters",
        "corcept",
        "therapeutic",
        "interim",
        "result",
        "relacorilant",
        "phase",
        "trial",
        "show",
        "evidence",
        "progesterone",
        "receptor",
        "affinity",
        "serious",
        "adverse",
        "relacorilant",
        "trial",
        "show",
        "statistically",
        "significant",
        "improvement",
        "glucose",
        "tolerance",
        "serum",
        "source",
        "text",
        "eikon",
        "company",
        "coverage"
    ]
}